Resolving the HIF paradox in pancreatic cancer.

Cancer Letters
Natividad R FuentesCullen M Taniguchi

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is currently the third leading cause of cancer-related deaths and has a 5-year survival rate of less than 10%, far below the ~70% national average for all cancers. This poor prognosis is driven by an extreme resistance to nearly all known cancer treatments, which has long been attributed to hypoxia driven interactions between tumor cells and the supporting stromal microenvironment. The cellular response to hypoxia is driven by the transcription factors known as the hypoxia inducible factors (HIFs), which have been hypothesized to play a role in the pathobiology of PDAC as well as a potential therapeutic target based on years of cell culture data. Attempts to validate the oncogenic role of HIF in PDAC through rigorous spontaneous tumor models have paradoxically shown that the HIFs may act as a tumor suppressor in epithelial cells. Here, we seek to resolve this paradox by discussing the roles of HIFs both in cancer cells and the supporting microenvironment and place them into context of current model systems that could be used to interrogate these interactions. We suggest that HIF may exert its oncogenic influences by modulating the form and function of the stroma rather than direct effects...Continue Reading

References

Jan 1, 1994·International Journal of Radiation Biology·P A Riley
Nov 10, 2000·International Journal of Radiation Oncology, Biology, Physics·A C KoongM Vierra
Dec 20, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Michael S WiesenerKai-Uwe Eckardt
Jun 5, 2003·Nature Medicine·Christopher W Pugh, Peter J Ratcliffe
Jul 3, 2007·Cancer Metastasis Reviews·Debbie Liao, Randall S Johnson
Feb 5, 2008·Cancer Research·Rosa F HwangCraig D Logsdon
Feb 9, 2008·Cell Death and Differentiation·S A Patel, M C Simon
Jul 22, 2008·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Mert ErkanJörg Kleeff
Aug 8, 2009·The Journal of Clinical Investigation·William Y KimKwok-Kin Wong
Jul 21, 2010·The Journal of Clinical Investigation·Hongxia Z ImtiyazM Celeste Simon
Jul 28, 2010·Proceedings of the National Academy of Sciences of the United States of America·Jolly MazumdarBrian Keith
Jan 22, 2011·Journal of Cellular and Molecular Medicine·Aude CarreauClaudine Kieda
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Jul 15, 2011·Nature·Andrea FacciabeneGeorge Coukos
Mar 20, 2012·The Journal of Clinical Investigation·Nicolas SkuliM Celeste Simon
Jun 20, 2012·Nature Reviews. Gastroenterology & Hepatology·Mert ErkanHelmut Friess
Aug 18, 2012·Biochimica Et Biophysica Acta·Elena FasanoGabriella Calviello
Feb 20, 2013·Journal of Cell Science·Frances R BalkwillThorsten Hagemann
Jun 12, 2013·Cancer Research·Angela CriscimannaFarzad Esni
Apr 17, 2014·Current Medicinal Chemistry·N A Warfel, W S El-Deiry
Apr 30, 2014·The Journal of Experimental Medicine·Muhammad Zaeem NomanSalem Chouaib
May 16, 2014·Science Translational Medicine·Cullen M TaniguchiAmato J Giaccia

❮ Previous
Next ❯

Citations

Oct 30, 2020·Cells·Claudia Geismann, Alexander Arlt
Aug 10, 2021·World Journal of Gastroenterology : WJG·Matias Estaras, Antonio Gonzalez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.

Related Papers

Current Sleep Medicine Reports
Jonathan C JunVsevolod Y Polotsky
Blood Cells, Molecules & Diseases
Parisa Imanirad, Elaine Dzierzak
© 2022 Meta ULC. All rights reserved